Citizens Maintains Market Outperform on MiMedx Group, Lowers Price Target to $6

Benzinga Newsdesk www.benzinga.com Negative 96.2%

Neg 96.2% Neu 0% Pos 0%

Citizens analyst David Turkaly maintains MiMedx Group (NASDAQ:MDXG) with a Market Outperform and lowers the price target from $7 to $6.